DeSci

Paul Kohlhaas's Molecule wrapped university research IP into NFTs that confer legal rights — licensing revenue, governance over commercialization decisions, and underlying patent ownership. The IP-NFT is a legal contract template plus a token; the token's holder is the legal counterparty. VitaDAO and other bio-DAOs use IP-NFTs to fund and own research portfolios. The mechanism turned 'invest in early-stage drug discovery' from a venture-only activity into something a community of 1,000 patient capital allocators could do without a fund structure.

BIO Protocol (incubated by Molecule, token launched 2024) is a launchpad for bio-DAOs. Each DAO funds a specific research domain — VitaDAO (longevity), HairDAO (hair loss), AthenaDAO (women's health), CryoDAO (cryopreservation) — and BIO holders curate which DAOs get listed and seeded. The unlock: a coherent meta-layer where bio-DAOs share liquidity, tokenomics templates, and IP-NFT infrastructure. Without BIO, each bio-DAO had to bootstrap independently. Backed by Vitalik Buterin and the broader DeSci coalition. The clearest infrastructure play in the sector.

Pump.science streams live longevity experiments on C. elegans (nematodes) to a public audience. Compounds — rifampicin, urolithin A, others — are dosed against control populations, and survival data updates publicly in real time. Each compound has a token; markets price the probability of lifespan extension as the experiment runs. The radical move is making the data primary and the discussion downstream of the data, instead of the other way around. A small experimental sample size in a popcorn format, but the rails are correct.

VitaDAO (2021, founded by Tyler Golato, Paul Kohlhaas, Vincent Weisser) is the longest-running bio-DAO. VITA token holders govern a treasury that funds longevity research projects — specific researchers, specific compounds, specific aging hypotheses. Funded research includes work on Korolchuk lab autophagy, Newcastle University proteostasis, and others. IP-NFTs flow into the DAO's portfolio. ~$10M+ deployed into research grants over its run. The reference example for what a bio-DAO actually looks like once it's been operating for years rather than weeks.

Brian Armstrong's ResearchHub pays RSC (ResearchCoin) for substantive peer review, replication, and publication of open-access papers. The pitch: scientific peer review is unpaid labor that gates the largest gatekept industry on Earth — pricing it changes the incentive landscape. Bounties on specific papers, on specific reviews, and on replication studies. Volume small relative to legacy publishing; signal real on the contributors who showed up. The bet is patient — it competes with a 350-year-old institution's habits.

Decentralized clinical trials use crypto rails for patient consent (on-chain attestation), data integrity (cryptographic timestamping of trial results), and direct patient-to-protocol payment for participation. Several bio-DAOs have piloted small-scale decentralized trials for nutraceutical and longevity compounds where the regulatory bar is lower than Phase II oncology. The full vision — community-funded, on-chain-coordinated FDA-grade trials — is years out and requires regulatory frameworks that don't yet exist. The early experiments are useful as training data for what does.